Bristol Myers doubles down in immuno-oncology patent fight with AZ, this time targeting Imjudo

In a lawsuit filed Monday in Delaware federal court, BMS alleged AstraZeneca’s new CTLA-4 inhibitor Imjudo—approved last year alongside AZ’s Imfinzi in liver and lung cancer—treads on a pair of patents linked to BMS' cancer blockbuster Yervoy.